Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics
- PMID: 20373018
- DOI: 10.1007/s10549-010-0853-8
Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics
Abstract
Double heterozygosity (DH) for BRCA1 and BRCA2 mutations is a very rare finding, particularly in non-Ashkenazi individuals, and only a few cases have been reported to date. In addition, little is known on the pathological features of the tumors that occur in DH cases and on their family history of cancer. Four carriers of pathogenic mutations in both BRCA1 and BRCA2 were identified among women who underwent genetic counseling for hereditary susceptibility to breast and ovarian carcinoma at three different Italian institutions. Clinical, pathological, and family history data were collected from medical records and during genetic counseling sessions. All identified DH cases developed breast carcinoma and three of them were also diagnosed with ovarian carcinoma. Mean ages of breast and ovarian cancer diagnosis were 42.7 and 48.6 years, respectively. The majority of breast cancers showed a BRCA1-related phenotype, being negative for hormone receptors and HER2. Two cases reported different gastrointestinal tumors among relatives. Although the individuals described in this study show more severe clinical features in comparison to previously reported BRCA1 and BRCA2 DH cases, our observations support the hypothesis of a non specific phenotype of DH cases in terms of age of disease onset. In addition, our observations indicate that in DH patients breast carcinogenesis appears to be driven mainly by the mutations in BRCA1. The possible association of DH for BRCA gene mutations with gastrointestinal tumors is in keeping with previous reports, but needs to be confirmed by further analyses.
Similar articles
-
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.Clin Cancer Res. 2002 Dec;8(12):3776-81. Clin Cancer Res. 2002. PMID: 12473589
-
Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.Breast Cancer Res Treat. 2010 Sep;123(2):581-5. doi: 10.1007/s10549-010-0818-y. Epub 2010 Mar 11. Breast Cancer Res Treat. 2010. PMID: 20221693
-
Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case report.Breast Cancer Res Treat. 2010 Dec;124(3):875-8. doi: 10.1007/s10549-010-1125-3. Epub 2010 Aug 21. Breast Cancer Res Treat. 2010. PMID: 20730485
-
Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.Gynecol Oncol. 2000 Sep;78(3 Pt 1):278-87. doi: 10.1006/gyno.2000.5861. Gynecol Oncol. 2000. PMID: 10985881 Review.
-
Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2.Hum Mutat. 2002 Dec;20(6):413-24. doi: 10.1002/humu.10154. Hum Mutat. 2002. PMID: 12442265 Review.
Cited by
-
Case Report: Clinical impact of BRCA1 and BRIP1 vs. BRCA1 and BRCA2 germline double heterozygosity in ovarian cancer: a comparative case study.Front Oncol. 2025 Jul 24;15:1614373. doi: 10.3389/fonc.2025.1614373. eCollection 2025. Front Oncol. 2025. PMID: 40777133 Free PMC article.
-
Double heterozygosity for BRCA1 and BRCA2 in breast cancer: considerations in surveillance and cancer risk management.BMJ Case Rep. 2025 Apr 22;18(4):e263687. doi: 10.1136/bcr-2024-263687. BMJ Case Rep. 2025. PMID: 40262912 Free PMC article.
-
A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2.Case Rep Oncol. 2021 Nov 18;14(3):1645-1651. doi: 10.1159/000520148. eCollection 2021 Sep-Dec. Case Rep Oncol. 2021. PMID: 35082620 Free PMC article.
-
Five Italian Families with Two Mutations in BRCA Genes.Genes (Basel). 2020 Dec 3;11(12):1451. doi: 10.3390/genes11121451. Genes (Basel). 2020. PMID: 33287145 Free PMC article.
-
Double Heterozygosity for Germline Mutations in Chinese Breast Cancer Patients.Cancers (Basel). 2024 Jul 15;16(14):2547. doi: 10.3390/cancers16142547. Cancers (Basel). 2024. PMID: 39061189 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous